Should I buy or sell ImmunoPrecise Antibodies stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPA shares. View IPA analyst ratings or view top-rated stocks .

What is ImmunoPrecise Antibodies' stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $5.00 to $9.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 464.5% from the stock's current price. View analysts price targets for IPA or view top-rated stocks among Wall Street analysts .

How have IPA shares performed in 2024?

ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of the year. Since then, IPA stock has decreased by 27.5% and is now trading at $1.24. View the best growth stocks for 2024 here .

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 318,200 shares, a decrease of 27.8% from the March 15th total of 440,700 shares. Based on an average daily trading volume, of 578,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.5% of the company's stock are short sold. View ImmunoPrecise Antibodies' Short Interest .

When is ImmunoPrecise Antibodies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 8th 2024. View our IPA earnings forecast .

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its earnings results on Thursday, March, 14th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $4.60 million for the quarter, compared to analysts' expectations of $4.43 million. ImmunoPrecise Antibodies had a negative trailing twelve-month return on equity of 26.54% and a negative net margin of 60.23%.

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free IPA Stock Alerts

$1.24

-0.03 (-2.36%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.17
▼
$1.28
50-Day Range: $1.24
▼
$2.20
52-Week Range: $0.94
▼
$4.22

Volume: 172,761 shs
Average Volume: 511,699 shs
Market Capitalization: $32.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get ImmunoPrecise Antibodies alerts:

ImmunoPrecise Antibodies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 464.5% Upside
$7.00 Price Target
Short Interest: Healthy
1.48% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.36) to ($0.26) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

482nd out of 919 stocks

Pharmaceutical Preparations Industry

212th out of 410 stocks

3.5

Analyst's Opinion

Consensus Rating
ImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ImmunoPrecise Antibodies has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.48% of the float of ImmunoPrecise Antibodies has been sold short.
Short Interest Ratio / Days to Cover
ImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ImmunoPrecise Antibodies has recently decreased by 27.80%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ImmunoPrecise Antibodies does not currently pay a dividend.
Dividend Growth
ImmunoPrecise Antibodies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPA.

1.3

News and Social Media Coverage

News Sentiment
ImmunoPrecise Antibodies has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
MarketBeat Follows
Only 3 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.
Percentage Held by Institutions
Only 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.36) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ImmunoPrecise Antibodies is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmunoPrecise Antibodies is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ImmunoPrecise Antibodies has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IPA Stock News Headlines

March 28, 2024 | finance.yahoo.com

InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

March 28, 2024 | businesswire.com

InterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 20, 2024 | businesswire.com

IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

March 15, 2024 | msn.com

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call Transcript

March 14, 2024 | investorplace.com

IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024

March 7, 2024 | finance.yahoo.com

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

March 7, 2024 | businesswire.com

IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 4, 2024 | finance.yahoo.com

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024

December 16, 2023 | markets.businessinsider.com

Buy Rating on ImmunoPrecise Antibodies Reflects Strong Revenue Growth and Cost Management Success

December 8, 2023 | finance.yahoo.com

IPA Announces Closing of $1.265 Million Public Offering of Common Shares

December 6, 2023 | benzinga.com

Why ImmunoPrecise Antibodies (IPA) Stock Is Down 20% Today

December 6, 2023 | investorplace.com

Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?

December 6, 2023 | finance.yahoo.com

IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

December 5, 2023 | investing.com

After-hours movers: SentinelOne up on earnings, MongoDB sees 'sell the news' reaction

December 5, 2023 | finance.yahoo.com

IPA Announces Proposed Public Offering of Common Shares

November 27, 2023 | businesswire.com

ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call

November 22, 2023 | finance.yahoo.com

ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

November 20, 2023 | benzinga.com

ImmunoPrecise's BioStrand® Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery

October 25, 2023 | stockhouse.com

IPA's Subsidiary, BioStrand, Provides an Update on LENSai(TM)

October 25, 2023 | benzinga.com

IPA's Subsidiary, BioStrand, Provides an Update on LENSai™

October 25, 2023 | financialpost.com

IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™

October 20, 2023 | finance.yahoo.com

Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data

October 20, 2023 | finance.yahoo.com

How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research

September 19, 2023 | finance.yahoo.com

ImmunoPrecise Antibodies Announces CFO Transition

September 18, 2023 | nasdaq.com

HC Wainwright & Co. Reiterates ImmunoPrecise Antibodies (IPA) Buy Recommendation

See More Headlines

Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/18/2024
Fiscal Year End: 4/30/2024
Next Earnings (Estimated): 7/08/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IPA
CUSIP: N/A
CIK: 1715925
Web: www.immunoprecise.com
Phone: 250-483-0308
Fax: N/A
Employees: 102
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $9.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +464.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,980,000.00
Net Margins: -60.23%
Pretax Margin: -66.12%
Return on Equity: -26.54%
Return on Assets: -18.36%

Debt

Debt-to-Equity Ratio: 0.25
Current Ratio: 1.66
Quick Ratio: 1.38

Sales & Book Value

Annual Sales: $15.61 million
Price / Sales: 2.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.74 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 26,320,000
Free Float: 24,518,000
Market Cap: $32.64 million
Optionable: Not Optionable
Beta: 0.09

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Jennifer Lynne Bath Ph.D.
CEO, President & Non-Independent Director
Dr. Ilse Roodink
Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
Ms. Kristin Taylor CPA
M.B.A., Chief Financial Officer
Mr. David E. Orton
Chief Operating Officer
Dr. Roland Romijn
Head of General Operations of the Utrecht site of IPA (Europe)

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IPA Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPA shares.
View IPA analyst ratings or view top-rated stocks.
What is ImmunoPrecise Antibodies' stock price target for 2024?: 2 equities research analysts have issued twelve-month price objectives for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $5.00 to $9.00. On average, they predict the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 464.5% from the stock's current price.
View analysts price targets for IPA or view top-rated stocks among Wall Street analysts.
How have IPA shares performed in 2024?: ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of the year. Since then, IPA stock has decreased by 27.5% and is now trading at $1.24.
View the best growth stocks for 2024 here.
Are investors shorting ImmunoPrecise Antibodies?: ImmunoPrecise Antibodies saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 318,200 shares, a decrease of 27.8% from the March 15th total of 440,700 shares. Based on an average daily trading volume, of 578,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.5% of the company's stock are short sold.
View ImmunoPrecise Antibodies' Short Interest.

When is ImmunoPrecise Antibodies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, July 8th 2024.
View our IPA earnings forecast.
How were ImmunoPrecise Antibodies' earnings last quarter?: ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its earnings results on Thursday, March, 14th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $4.60 million for the quarter, compared to analysts' expectations of $4.43 million. ImmunoPrecise Antibodies had a negative trailing twelve-month return on equity of 26.54% and a negative net margin of 60.23%.
How do I buy shares of ImmunoPrecise Antibodies?: Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial